"It gives me a sense of belonging": Providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group

International Journal of Drug Policy

Volumn 24, Issue 6, 2013, Pages 550-557

  Woolhouse, Susan ^a,b   Cooper, Emily ^a   Pickard, Angela ^c  

^a South Riverdale Community Health Centre   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Group cohesion; Hepatitis C virus; Interprofessional care; Psycho educational group; Qualitative research; Substance abuse

Indexed keywords

ADULT; ARTICLE; BEHAVIOR CHANGE; CLINICAL ARTICLE; EMOTIONAL ATTACHMENT; FEMALE; GROUP DYNAMICS; GROUP STRUCTURE; HEPATITIS C; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MALE; MOTIVATION; PEER GROUP; PHENOMENOLOGY; PRIORITY JOURNAL; PROGRAM ACCEPTABILITY; PSYCHOEDUCATION; QUALITATIVE RESEARCH; RANDOM SAMPLE; SEMI STRUCTURED INTERVIEW; SOCIAL INTERACTION; SUBSTANCE ABUSE; SUPPORT GROUP; ADAPTIVE BEHAVIOR; ATTITUDE TO HEALTH; CANADA; CLINICAL TRIAL; COMPLICATION; DECISION MAKING; DRUG USE; GROUP PROCESS; HEALTH BEHAVIOR; HUMAN RELATION; INTERVIEW; MIDDLE AGED; MULTICENTER STUDY; PATIENT EDUCATION; PROGRAM EVALUATION; PSYCHOLOGY; SELF HELP; SOCIAL DISTANCE; TIME; TRANSMISSION; TREATMENT OUTCOME;

ADAPTATION, PSYCHOLOGICAL; ADULT; DELIVERY OF HEALTH CARE, INTEGRATED; DRUG USERS; FEMALE; GROUP PROCESSES; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C; HUMANS; INTERPERSONAL RELATIONS; INTERVIEWS AS TOPIC; JUDGMENT; MALE; MIDDLE AGED; ONTARIO; PATIENT EDUCATION AS TOPIC; PROGRAM EVALUATION; QUALITATIVE RESEARCH; SELF-HELP GROUPS; SOCIAL DISTANCE; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890429652     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2013.05.018     Document Type: Article

References (54)

1. American Group Psychotherapy Association The American group psychotherapy association: Practice guidelines for group psychotherapy 2007, http://www.agpa.org/guidelines/AGPA%20Practice%20Guidelines%202007-PDF.pdf (Accessed 28.01.13).
2. Backmund M., Meyer K., Von Zielonka M., Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001, 34:188-193.
3. Beinart N., Weinman J., Wade D., Brady R. Caregiver burden and psychoeducational interventions in Alzheimer's disease: A review. Dementia and Geriatrics Cognitive Disorders Extra 2012, 2:638-648.
4. Borkan J. Chapter 10: immersion/crystallization. Doing qualitative research 1999, Sage Publications, Thousand Oaks, California. 2nd ed. B.F. Crabtree, L.M. Miller (Eds.).
5. Butt G., Paterson B.L., McGuinness L.K. Living with the stigma of hepatitis C. Western Journal of Nursing Research 2008, 30:204-221.
6. Carey T.A. A qualitative study of a social and emotional well-being service for a remote Indigenous Australian community: Implications for access, effectiveness, and sustainability. BMC Health Services Research 2013, 13:80.
7. Casanas R., Catalan R., Juis del Val J., Real J., Valero S.l., Casas M. Effectiveness of a psycho-educational group program for major depression in primary care: A randomized controlled trial. BMC Psychiatry 2012, 12(230).
8. Center for Substance Abuse Treatment Substance abuse treatment: group therapy. Treatment improvement protocol (TIP) series 2005, 41 Substance Abuse and Mental Health Services Administration (US), Rockville, MD.
9. Charlebois A., Lee L., Cooper E., Mason K., Powis J. Factors associated with HCV antiviral treatment uptake among participants of a community based program for marginalized patients. Journal of Viral Hepatology 2012, 19:836-842.
10. Chen J.C., Dodd Z., Khandor E., Mason K. The street health report 2007 research bulletin #1: Homelessness & hepatitis C 2008, Street Health, Toronto.
11. Chopra A., Klein P.L., Drinnan T., Lee S.S. How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver International: Official Journal of the International Association of the Study of the Liver 2013, 33(1):30-34.
12. Cornberg M., Razavi H.A., Alberti A., Bernasconi E., Buti M., Cooper C., et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International 2011, 31:30-60.
13. Dermatis H., Galanter M., Trujillo M., Rahman-Dujarric C., Ramaglia K., LaGressa D. Evaluation of a model for the treatment of combined mental illness and substance abuse: The Bellevue model for peer-led treatment in systems change. Journal of Addictive Disease 2006, 25:69-78.
14. Dimova R.B., Zeremski M., Jacobson I.M., Des Jarlais D.C., Talal A.H. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clinical Infectious Diseases 2013, 56:806-816.
15. Doab A., Treloar C., Dore G.J. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Diseases 2005, 40(Suppl. 5):S313-S320.
16. Galindo L., Maginnis T., Wallace G., Hansen A., Sylvestre D. Education by peers is the key to success. International Journal of Drug Policy 2007, 18:411-416.
17. Gallagher M.E., Tasca G.A., Ritchie K., Balfour L., Maxwell H., Bissada H. Interpersonal learning is associated with improved self-esteem in group psychotherapy for women with binge eating disorder. Psychotherapy (Chicago III) 2013, February 11 (epub).
18. Gilchrist V.J., Williams R.L. Chapter 4: Key informant interviews. Doing qualitative research 1999, Sage Publications, Thousand Oaks, California. 2nd ed. B.F. Crabtree, L.M. Miller (Eds.).
19. Grebely J., Genoway K., Khara M., Duncan F., Viljoen M., Elliott D., et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. International Journal of Drug Policy 2007, 18:437-443.
20. Grebely J., Raffa J.D., Meagher C., Duncan F., Genoway K.A., Khara M., et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. Journal of Gastroenterology & Hepatology 2007, 22:1519-1525.
21. Grebely J., Raffa J.D., Lai C., Krajden M., Kerr T., Fischer B., et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. Journal of Viral Hepatology 2009, 16:352-358.
22. Grebely J., Knight E., Genoway K., Viljoen M., Khara M., Elliott D., et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: A novel model incorporating multidisciplinary care and peer support. European Journal of Gastroenterology & Hepatology 2010, 22:270-277.
23. Goering P., Durbin J., Ochocka J., Sheldon C.T., Nelson G., Krupa T. Who uses consumer-run self-help organizations?. American Journal of Orthopsychiatry 2006, 76:367-373.
24. Health Canada I-track: Enhanced surveillance of risk behaviours among injecting drug users in Canada (pilot survey report) 2004, Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada, Ottawa, ON.
25. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases 2009, 49:561-573.
26. John-Baptiste A., Varenbut M., Lingley M., Nedd-Roderique T., Teplin D., Tomlinson G., et al. Treatment of hepatitis C infection for current or former substance abusers in a community setting. Journal of Viral Hepatology 2009, 16:557-567.
27. Khandor E., Mason K. Research bulletin #3: Homelessness and crack 2008, Street Health, Toronto.
28. Kwong J.C., Crowcroft N.S., Campitelli M.A., Ratnasingham S., Daneman N., Deeks S.L., et al. Ontario Burden of Infectious Disease Study Advisory Group. Ontario Burden of Infectious Disease Study (ONBOIDS): An OAHPP/ICES Report. Toronto: Ontario Agency for Health Protection and Promotion. Institute for Clinical Evaluative Sciences 2010.
29. Lipman E.L., Waymouth M., Gammon T., Carter P., Secord M., Leung O., et al. Influence of group cohesion on maternal well-being among participants in a support/education group program for single mothers. American Journal of Orthopsychiatry 2007, 77:543-549.
30. MacNair-Semands R. Predicting attendance and expectations for group therapy. Group Dynamics: Theory, Research, and Practice 2002, 6:219-228.
31. Matthews G., Kronborg I.J., Dore G.J. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clinical Infectious Diseases 2005, 40:S325-S329.
32. Morse J.M., Richards L. Readme first for a user's guide to qualitative methods 2002, Sage Publications, Thousand Oaks, California.
33. Myers R.P., Ramji A., Bilodeau M., Wong S., Feld J.J. An update on the management of chronic hepatitis C: Consensus guidelines from the Canadian Association for the Study of the Liver. Canadian Journal of Gastroenterology 2012, 26:359-375.
34. Myles A., Mugford G.J., Zhao J., Krahn M., Wang P.P. Physicians' attitudes and practice toward treating injection drug users infected with hepatitis C virus: Results form a national specialist survey in Canada. Canadian Journal of Gastroenterology 2011, 25:135-139.
35. Patrick D.M., Buxton J.A., Bingham M., Mathias R.G. Public health and hepatitis C. Canadian Journal of Public Health 2000, 91(1):S18-S23.
36. Rekart M.L. Sex-work harm reduction. The Lancet 2005, 366:2123-2134.
37. Remis R.S. Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada 2007. Final report. Community Acquired Infections Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada 2007, Available at: http://epe.lac-bac.gc.ca/100/200/301/phac-aspc/modeling_hepatis_c_infection-e/HP40-39-2009E.pdf (Accessed 07.05.13).
38. Schaefer M., Heinz A., Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules?. Addiction 2004, 99:1167-1175.
39. Schaefer M., Hintzpeter A., Mohmand A., Janssen G., Pich M., Schwaiger M., et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology 2007, 46:991-998.
40. Sherman S.G., German D., Cheung Y., Marks M., Bailey-Kloche M. The evaluation of the JEWEL project: An individual economic enhancement and HIV prevention intervention study targeting drug using women involved in prostitution. AIDS Care 2006, 18:1-11.
41. Sherman M., Shafran S., Burak K., Doucette K., Wong W., Girgrah N., et al. Management of chronic hepatitis C: Consensus guidelines. Canadian Journal of Gastroenterology 2007, 21(Suppl. C):25C-34C.
42. Sockalingam S., Chammi C., Stergiopoulos V. Managing the neuropsychiatric complications of hepatitis C treatment. British Journal of Hospital Medicine (London) 2007, 68:520-525.
43. Starks H., Trinidad S.B. Choose your method: A comparison of phenomenology, discourse analysis and grounded theory. Qualitative Health Research 2007, 17:1372-1380.
44. Stein M.R., Soloway I.J., Jefferson K.S., Roose R.J., Arnsten J.H., Litwin A.H. Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 2012, 43:424-432.
45. Strathdee S.A., Latka M., Campbell J., O'Driscoll P.T., Golub E.T., Pollini R., et al. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clinical Infectious Diseases 2005, 40(Suppl. 5):S304-S312.
46. Street Health The crack users project: A manual 2007, Street Health, Toronto.
47. Sword W., Niccols A., Fan A. "New Choices" for women with addictions: Perceptions of program participants. BMC Public Health 2004, 4:10.
48. Sylvestre D.L. Treating hepatitis C virus infection in active substance users. Clinical Infectious Diseases 2005, 40(Suppl. 5):S321-S324.
49. Sylvestre D.L., Zweben J.E. Integrating HCV services for drug users: A model to improve engagement and outcomes. International Journal of Drug Policy 2007, 18:406-410.
50. Treloar C., Rhodes T. The Lived experience of hepatitis C and its treatment among injecting drug users: Qualitative synthesis. Qualitative Health Research 2009, 9:1321-1334.
51. Woolhouse S., Brown J.B., Thind A. Meeting people where they're at": Experiences of family physicians engaging women who use illicit drugs. Annals of Family Medicine 2011, 9:244-249.
52. World Health Organization The world health report 1998-life in the 21st century: A vision for all. Weekly Epidemiological Record 1998, 73:145-152.
53. Yalom I.D., Leszcz M. The theory and practice of group psychotherapy 2005, Basic Books, New York, NY. 5th ed.
54. Zou S., Forrester L., Giulivi A. Hepatitis C update. Canadian Journal of Public Health 2003, 94:127-129.